ACAD — ACADIA Pharmaceuticals Inc.
Is ACAD overbought or oversold? Here is the current MarketMoodz read.
ACADIA Pharmaceuticals Inc. (ACAD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $18.32. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$18.32
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
ACADIA Pharmaceuticals Inc. (ACAD) maintains a stable near‑term cash flow profile from its marketed product(s), but growth is contingent on successful pipeline readouts and label expansions. The company faces moderately elevated commercial and payer risk given recent Medicare Advantage regulatory attention and an active competitive field in CNS indications. Absent a clear near‑term positive catalyst, expect consolidation around current levels with upside tied to positive clinical/regulatory developments and downside from reimbursement or trial setbacks.
Key factors
- Established commercial franchise with recurring revenue from existing approved products providing baseline cash flow
- Limited near-term catalyst visibility: pipeline readouts and label-expansion events are the primary drivers of material upside
- Payer and reimbursement environment (Medicare Advantage regulatory changes) could tighten access or increase prior‑authorization friction
- Competitive landscape in neuropsychiatric and specialty CNS indications remains active, pressuring long‑term share without clear differentiation
- Macro/market environment favoring defensive large‑cap pharma limits sectorwide flows into small specialty biotechs in the near term
Risks
- Negative clinical trial results or delays in ongoing development programs that would reduce future revenue potential
- Increased payer resistance, pricing pressure, or Medicare clawbacks that reduce realized net price and volume
- Regulatory or labeling setbacks that could restrict indications or market access
- Commercial execution risks, including loss of market share to competing therapies
- Need for additional capital or dilutive financings if cash runway is insufficient to reach key milestones
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ACAD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.